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Summary
Rapamycin, an inhibitor of the mechanistic target of rapamycin
(mTOR) signaling pathway, extends the life span of yeast, worms,
flies, and mice. Interventions that promote longevity are often
correlated with increased insulin sensitivity, and it therefore is
surprising that chronic rapamycin treatment of mice, rats, and
humans is associated with insulin resistance (J Am Soc Nephrol.,
19, 2008, 1411; Diabetes, 00, 2010, 00; Science, 335, 2012, 1638).
We examined the effect of dietary rapamycin treatment on
glucose homeostasis and insulin resistance in the genetically
heterogeneous HET3 mouse strain, a strain in which dietary
rapamycin robustly extends mean and maximum life span. We
find that rapamycin treatment leads to glucose intolerance in
both young and old HET3 mice, but in contrast to the previously
reported effect of injected rapamycin in C57BL/6 mice, HET3 mice
treated with dietary rapamycin responded normally in an insulin
tolerance test. To gauge the overall consequences of rapamycin
treatment on average blood glucose levels, we measured HBA1c.
Dietary rapamycin increased HBA1c over the first 3 weeks of
treatment in young animals, but the effect was lost by 3 months,
and no effect was detected in older animals. Our results
demonstrate that the extended life span of HET3 mice on a
rapamycin diet occurs in the absence of major changes in insulin
sensitivity and highlight the importance of strain background
and delivery method in testing effects of longevity interventions.
Key words: aging; glucose tolerance; heterogeneous mice;
insulin tolerance; rapamycin.
Introduction
Calorie restriction (CR), an intervention in which total caloric intake
is reduced while maintaining nutrition, extends the life span of
yeast, worms, flies, and mammals, including mice, rats, dogs, and
primates. A CR diet [and often even diet restriction (DR), in which
amounts of the diet are simply reduced] prevents or delays the
incidence of numerous age-related diseases, including type 2
diabetes. Accordingly, there is significant interest in identifying
small molecules that mimic the beneficial effects of a CR diet. The
National Institute on Aging Interventions Testing Program (ITP) tests
the effects of anti-aging interventions on mouse longevity at three
independent sites, using genetically heterogeneous HET3 mice.
HET3 mice are the F2 progeny of (BALB/cJ 9 C57BL/6J) mothers
and (C3H/HeJ 9 DBA/2J) fathers and provide a heterogeneous yet
reproducible genetic background in which the causes of age-related
mortality will be varied (Flurkey et al., 2010). To date, the molecule
in this program that demonstrates the most robust extension of
both average and maximum life spans is rapamycin (Harrison et al.,
2009; Miller et al., 2011).
Rapamycin is a specific inhibitor of the mechanistic target of
rapamycin (mTOR), a protein kinase that is found in two complexes
with distinct cellular targets. mTORC1, the canonical target of
rapamycin, regulates many processes related to growth, including
ribosomal biogenesis, cap-dependent translation, and autophagy.
mTORC2, which regulates Akt, SGK, and PKCa activity, is resistant
to acute treatment with rapamycin. However, chronic treatment
disrupts mTORC2 signaling in some cell lines (Sarbassov et al.,
2006).
We recently showed that chronic treatment with rapamycin
disrupts mTORC2 signaling in vivo (Lamming et al., 2012). Rapa-
mycin treatment of young BALB/c mice (Cunningham et al., 2007)
and C57BL/6 mice (Lamming et al., 2012) for 2–3 weeks leads to
glucose intolerance and hepatic insulin resistance, mediated by the
disruption of mTORC2 (Lamming et al., 2012). Chronic rapamycin
treatment of C57BL/6 mice may also lead to mTORC1-mediated
skeletal muscle insulin resistance (Cunningham et al., 2007; Blattler
et al., 2012). Young Sprague–Dawley rats chronically treated with
rapamycin develop glucose intolerance and insulin resistance and
have increased hepatic gluconeogenesis (Houde et al., 2010).
Similar results have also been observed in humans treated with
rapamycin, with kidney transplant patients receiving rapamycin
displaying increased insulin sensitivity, and the 3-year incidence of
diabetes increasing to nearly 22% in rapamycin-treated patients,
compared with 16–19% in patients receiving alternative treatment
(Teutonico et al., 2005; Johnston et al., 2008).
Treatments that increase life span frequently also increase insulin
sensitivity, as observed in mice on a CR diet as well as in the long-
lived Ames and Snell dwarf mice, as well as many genetically
modified mice (Dominici et al., 2002; Selman et al., 2009; Foukas
et al., 2013). While certain genetically modified mice strains have
both increased insulin resistance and increased longevity (Selman
et al., 2008), decreased insulin sensitivity in both mice and humans
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is more typically associated with decreased life span (Hogan et al.,
2003; Baur et al., 2006). It is therefore fascinating that rapamycin
decreases glucose tolerance and insulin sensitivity in the context of
increased life span.
However, studies of the effects of rapamycin on glucose
homeostasis have been performed exclusively in young, inbred
rodent strains given rapamycin by intraperitoneal injections for only
a few weeks. In contrast, major longevity studies using rapamycin
have been performed in genetically heterogeneous HET3 mice, with
dietary rapamycin treatment beginning at 9 or 20 months of age
and persisting until death. Thus, to better understand the paradox-
ical effects of rapamycin on diabetic phenotypes, we examined
glucose homeostasis and insulin sensitivity in both young and old
HET3 mice treated with dietary rapamycin for either 3 weeks or
3 months.
Results
Rapamycin treatments were scheduled, so our analyses below of
3-week and 3-month treatments were done when HET3 mice were
6 or 21 months of age. Fasted weights taken just before testing
showed no statistically significant differences, although young mice
fed rapamycin tended to be lighter than age-matched controls,
while old mice fed rapamycin tended to be heavier than age-
matched controls.
Rapamycin significantly decreased glucose tolerance in both
young (Fig. 1A) and old (Fig. 1B) HET3 mice. The length of
rapamycin treatment did not significantly affect the area under
the curve (Fig. 1C), although the area tended to be higher in young
mice given rapamycin for 3 months. These results are consistent
with previous findings that rapamycin treatment of C57BL/6 mice
and Sprague–Dawley rats increases gluconeogenesis and induces
hepatic insulin resistance (Houde et al., 2010; Lamming et al.,
2012).
We also tested the response of rapamycin-fed mice to pyruvate, a
key substrate for gluconeogenesis. Impaired tolerance to pyruvate
indicates a failure to suppress hepatic gluconeogenesis. We found
that young HET3 mice treated with rapamycin for 3 months
(Fig. 1D), as well as old HET3 mice treated with rapamycin for
either 3 weeks or 3 months (Fig. 1E), had significantly decreased
pyruvate tolerance (Fig. 1F).
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Fig. 1 Rapamycin treatment results in glucose and pyruvate intolerance in HET3 mice. Glucose tolerance test on (A) young (6-month-old) and (B) old (21-month-old) mice
treated with rapamycin for short (3 weeks) or long (3 months) periods. (C) Quantitation of area under the curve of glucose tolerance tests in (A) and (B). (A–C: **P < 0.01,
*P < 0.04, #P < 0.07 vs. control mice, two-tailed t-test). Pyruvate tolerance was tested 2 weeks after glucose tolerance in the same mice and is decreased in (D) young mice
treated with rapamycin for 3.5 months (*P < 0.05, young rapamycin-long vs. control mice, two-tailed t-test) and in (E) old mice treated with rapamycin for 5 weeks or
3.5 months (*P < 0.05, old rapamycin groups vs. old control mice, two-tailed t-test; at t = 0, P < 0.05 for rapamycin long vs. control only). (F) Quantitation of area under
the curve of pyruvate tolerance tests in D and E. (D–F: *P < 0.05, two-tailed t-test).
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In C57BL/6 mice and Sprague–Dawley rats, rapamycin treatment
significantly induces insulin resistance, as measured by an insulin
tolerance test (ITT) (Houde et al., 2010; Blattler et al., 2012;
Lamming et al., 2012). Surprisingly, and in contrast to these results,
we found that dietary rapamycin did not induce insulin resistance in
HET3 mice as measured by ITT in either young (Fig. 2A) or old
(Fig. 2B) mice, even when given to mice over a 3-month period.
Interestingly, Fok et al., (2012) have recently reported that dietary
rapamycin caused glucose intolerance in the absence of any effect
on insulin tolerance in C57BL/6 mice, suggesting that the delivery
method, rather than the strain, may be the major determinant of
whether mice develop overt insulin resistance. In concurrence with
our previous study in C57BL/6 mice, HET3 mice treated with
rapamycin are hyperglycemic after refeeding and when young and
treated with rapamycin for 3 months, also display fasting hypergly-
cemia (Fig. 2C).
Rapamycin has been reported to negatively impact glucose-
stimulated insulin release by pancreatic beta cells in C57BL/6 mice
(Yang et al., 2012). We observed no significant differences in insulin
levels between control mice and rapamycin-treated mice in either
the fasting or refed state, in either young or old mice (Fig. 2D). We
performed a glucose-stimulated insulin secretion (GSIS) assay
(Fig. 2E). In contrast to the results reported in C57BL/6 mice,
rapamycin caused no significant decrease in insulin levels following
0
20
40
60
80
100
0 20 40 60 80
Bl
oo
d 
gl
uc
os
e 
(%
 o
f b
as
al
)
Bl
oo
d 
gl
uc
os
e 
(%
 o
f b
as
al
)
Time (min)
0
20
40
60
80
100
0 20 40 60 80
Young control
Young rapamycin - short
Young rapamycin - long
Old control
Old rapamycin - short
Old rapamycin - long
0
0.5
1
1.5
2
In
su
lin
 (n
g 
m
L–
1 )
In
su
lin
 (n
g 
m
L–
1 )
In
su
lin
 (n
g 
m
L–
1 )
0
0.5
1
1.5
2
0
20
40
60
80
100
120
140
Fasting Refed Fasting Refed Fasting Refed Fasting Refed
Bl
oo
d 
gl
uc
os
e 
(m
d 
dL
–1
)
0
20
40
60
80
100
120
140
Bl
oo
d 
gl
uc
os
e 
(m
d 
dL
–1
)
*
**
#
##
** **
Control Rapamycin - short Rapamycin - longControl Rapamycin - short Rapamycin - long
Young Old Young Old
0
1
2
3
Young Old
H
O
M
A
2-
IR
0
0.5
1
1.5
Young Old
Control
Rapamycin - short
Rapamycin - long
ITT ITT
GSIS ##
#
#
##
0
0.5
1
1.5
2
H
bA
1c
 %
 (m
m
ol
 m
ol
–1
)
Young Old
Control Rapamycin - short Rapamycin - long
*
Time (min)
(A) (B)
(C) (D)
(E) (F)
Fig. 2 Rapamycin treatment does not affect insulin resistance or insulin levels in HET3 mice. Insulin tolerance was tested 1 week after glucose tolerance in the same mice:
(A) young (6-month-old) and (B) old (21-month-old) mice treated with rapamycin for 4 weeks or 3.3 months. (A: *P < 0.05 vs. control mice, two tailed t-test.) (C–D) Mice
were fasted overnight and then refed for 4 h, and (C) blood glucose and (D) insulin were measured in both feeding states (C: **P < 0.01, #P = 0.059, ##P = 0.073 vs.
control mice, two tailed t-test; D: #P = 0.16, ##P = 0.173 vs. control mice, two tailed t-test). (E) Left: HOMA-IR was calculated using the fasting glucose and insulin data in C
and D. Right: Glucose-stimulated insulin secretion (GSIS) was measured by fasting mice overnight, injecting 1 g kg1 glucose, and collecting serum 15 min postinjection
(#P < 0.124, ##P = 0.128 vs. control mice, two tailed t-test). (F) HbA1c was measured on whole blood (*P < 0.05, two-tailed t-test).
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glucose injection, and old mice treated with rapamycin for 3 months
had a trend toward hyperinsulinemia. However, insulin levels in
several experimental groups are inappropriately normal despite
significantly elevated glucose levels, suggesting that rapamycin may
have an impact on beta cell function (Fig. 2C,D).
Finally, we used the fasted blood glucose and insulin levels to
calculate insulin resistance using homeostasis model assessment
(HOMA2-IR) (Levy et al., 1998). The HOMA2-IR model was derived
empirically from human insulin–glucose clamp data, but is equally
useful as a surrogate measure of insulin resistance in mice (Mather,
2009). We observed a trend toward decreased insulin resistance in
old mice treated with rapamycin for a short period of time
(P = 0.073, two-tailed t-test) and did not find increased insulin
resistance in any rapamycin-treated mice (Fig. 2E). To determine the
cumulative effect of hepatic insulin resistance on blood glucose
levels over time, we measured the level of glycated hemoglobin
(HbA1c). While there was a significant increase in HbA1c in young
mice treated with rapamycin for 3 weeks, there was no increase in
HbA1c observed in young mice treated with rapamycin for
3 months, or in old mice treated with rapamycin (Fig. 2F).
As these data suggest the surprising result that HET3 mice treated
with dietary rapamycin for a prolonged time do not have a defect in
insulin tolerance and do not experience a major increase in average
blood glucose levels, we examined the effect of rapamycin on male
and female HET3 mice in an independent cohort of mice treated
with rapamycin starting at approximately 20 months of age for
6–8 months. We found no significant difference in insulin resistance
in rapamycin-treated mice relative to age-matched controls (Fig. 3A,
B). While fasting blood glucose in female mice treated with
rapamycin was similar to age-matched controls, male mice treated
with rapamycin for 20 months were hypoglycemic during fasting
(Fig. 3C). Neither males nor females had altered HbA1c levels
relative to age-matched controls (Fig. 3D). We also examined the
serum level of fructosamine, which, like HbA1c, reflects average
serum glucose levels and found that fructosamine levels were
decreased in rapamycin-treated female mice and increased in male
mice compared with old controls (Fig. 3D).
Discussion
In genetically heterogeneous HET3 mice, dietary rapamycin
increased life span when treatment was started at 20 months of
age (Harrison et al., 2009) or 9 months of age (Miller et al., 2011).
However, in young C57BL/6 and BALB/c inbred mice, rapamycin
treatment decreased glucose tolerance and increased insulin resis-
tance (Cunningham et al., 2007; Lamming et al., 2012), a surprising
result which runs counter to both intuition and a significant
correlation between insulin sensitivity and longevity. To clarify, we
analyzed both short-term and long-term treatment with dietary
rapamycin in young and old HET3 mice.
Concurring with our previous study in C57BL/6 mice, HET3 mice
treated with rapamycin were hyperglycemic after refeeding
(Fig. 2C) and when young and treated with rapamycin for
3 months, also displayed fasting hyperglycemia. Hyperglycemia
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Fig. 3 Rapamycin treatment does not negatively impact insulin tolerance or HbA1c levels in older HET3 mice treated for 5–7 months. Insulin tolerance test was performed
on (A) female and (B) male HET3 mice. Average ages for female (F) and male (M) mice are given in months: young control (F, 13.0; M, 11.6), old control (F, 27.5; M, 25.7);
old mice on rapamycin from 20 months of age (F, 27.4; M, 25.4). (C) Old male and female controls have fasting hyperglycemia relative to young controls and (female only)
relative to rapamycin-treated old mice (*P < 0.006, two-tailed t-test). (D) HbA1c and fructosamine were measured in the same mice. There was no effect of age or
rapamycin on HbA1c levels; however, fructosamine was lower in old female mice treated with rapamycin compared with controls (**P < 0.01) and trended higher in old
males receiving rapamycin (*P < 0.06, two-tailed t-tests).
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and glucose intolerance are the first symptoms of type 2 diabetes in
humans, but changes in HbA1c were observed only in young mice
treated for a short period of time compared with age-matched
controls (Figs 2F and 3D, discussed below). The phenotype of HET3
mice treated with rapamycin for a prolonged time is strikingly similar
to that of mice lacking the hepatic Rictor gene, which exhibit
glucose and pyruvate intolerance but display an essentially normal
response to an insulin tolerance test (Lamming et al., 2012). Just as
with HET3 mice treated with rapamycin, mice lacking Rictor display
hyperglycemia and hyperinsulinemia following refeeding. While we
found that the decrease in glucose tolerance in rapamycin-treated
C57BL/6 mice was largely attributable to the disruption of hepatic
mTORC2, Blattler et al. (2012) have proposed an alternative
mechanism by which rapamycin can decrease the expression of
insulin signaling components in skeletal muscle. It will be important
to dissect the relative contributions of these two mechanisms to the
effects of dietary rapamycin in both young and old HET3 mice in
future studies.
To determine whether the defective glucose homeostasis in the
HET3 mice leads to increased average blood glucose levels, we
assayed glycated hemoglobin (HbA1c). Surprisingly, while there was
an increase in HbA1c levels in young mice treated with rapamycin
for 3 weeks, we observed no changes in young mice treated for
3 months or in older mice regardless of treatment time (Figs 2F and
3D). This suggests that during the course of the initial ITP life span
study using 20-month-old mice, rapamycin-treated HET3 mice did
not experience higher average blood glucose levels. Even mice used
in the follow-up life span study, which initiated treatment at
9 months of age, probably experienced little or no increased blood
glucose. These data may resolve the seeming paradox of rapamycin
promoting life span in the context of glucose intolerance and
suggest that impaired glucose tolerance, but not necessarily
systemic insulin resistance, is compatible with increased longevity.
These data may resolve the seeming paradox that rapamycin
increases life span in the context of glucose intolerance. They
suggest that impaired glucose tolerance, but not necessarily
systemic insulin resistance, is compatible with increased longevity.
This contradicts the common conception that impaired glucose
tolerance will negatively affect mammalian life span.
While rapamycin treatment of inbred mouse and rat strains
results in clear insulin resistance, HET3 mice on the ITP rapamycin
diet do not exhibit overt defects in an insulin tolerance test and do
not display insulin resistance as calculated by the HOMA-IR method
(Fig 2). It remains possible that HET3 mice on a rapamycin diet
exhibit a smaller degree of insulin resistance that could be revealed
with the aid of insulin–glucose clamps in a future study.
An important question raised by this study is the applicability of
the rapamycin life span study to the clinic. Rapamycin treatment of
transplant patients leads to hyperglycemia and insulin resistance,
with an increased risk of diabetes (Johnston et al., 2008), but the
effect of rapamycin on healthy human adults has not been
extensively analyzed. C57BL/6 mice, which become insulin resistant
when treated with rapamycin, may therefore more closely mimic the
clinical experience of transplant patients than the insulin-sensitive
HET3 mice. Of course, HET3 mice better model a genetically diverse,
healthy human population, and using mice of mixed background
ensures that results are not observed due to strain-specific lesions.
Our findings highlight the importance of genetic background in
biomedical research. Finally, rapamycin may extend life span in aged
C57BL/6 mice despite the negative impact on insulin sensitivity; a
recent small study observed a decreased mortality rate in 22- to
24-month-old C57BL/6 mice injected for 6 weeks with rapamycin
(Chen et al., 2009). Subsequent efforts should focus on determining
the effects of strain background and delivery method on the
ultimate effects of rapamycin on longevity.
Experimental procedures
Animals
BALB/cJ 9 C57BL/6J F1 female mice (CB6F1/J, JAX stock #
100007) and C3H/HeJ 9 DBA/2J F1 male mice (C3D2F1/J, JAX
stock # 100004) were obtained from The Jackson Laboratory and
bred to produce heterogeneous HET3 F2 mice, a reproducible
genetic background. The Jackson Laboratory is fully accredited by
the American Association for Accreditation of Laboratory Animal
Care, and all studies were conducted under a protocol approved by
its the Animal Care and Use Committee (ACUC). Mice were
produced and maintained in double-sided plastic cages in isolated
rooms under positive pressure with high efficiency particulate air-
filtered air at room temperature (24  1 °C), lighted from 6 am to
6 pm. After weaning, mice were housed four per side with others
of the same sex and treatment. Results of quarterly screening for
pathogens and other microorganisms at The Jackson Laboratory
are provided online at http://jaxmice.jax.org/genetichealth/index.
html. Mice in this study were housed in room D1, which did not
have any pathogens for which The Jackson Laboratory routinely
tests. We did not have to censor data due to ill health or loss of
mice at The Jackson Laboratory or at MIT. During the studies at
MIT, mice in this study were housed as sole occupants of a second-
stage quarantine room and were not monitored for pathogens
during the course of the experiment. The diet was the same as at
The Jackson Laboratory. All experiments were approved by the
Institutional Animal Care and Use Committees at MIT and were
performed under the supervision of the MIT Department of
Comparative Medicine.
Rapamycin treatment protocol
Fourteen ppm rapamycin was encapsulated in chow, LabDiet 5LG6
(PMI Nutrition International, Bentwood, MO, USA); this is detailed
by Harrison et al. (2009). Age-matched control mice were fed a
5LG6 control diet without rapamycin. Young (6 months old) and old
(21 months old) mice were fed rapamycin for either 3 weeks or
3 months. Three weeks is similar to conditions in our previous
studies using C57BL/6J mice (Lamming et al., 2012); 3 months is
more reflective of conditions in the rapamycin study in the ITP
(Harrison et al., 2009; Miller et al., 2011). Rapamycin was fed to the
treated mice throughout these experiments. The first assay done in
the mice was glucose tolerance, insulin tolerance was tested a week
later, and pyruvate tolerance 2 weeks later.
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Tolerance tests and assays
Glucose, insulin, and pyruvate
Glucose, insulin, and pyruvate tolerance tests were performed by
fasting the mice overnight for 16 h and then injecting either
glucose (1 g kg1), insulin (0.75U kg1), or pyruvate (2 g kg1)
intraperitoneally as previously described (Lamming et al., 2012).
Glucose measurements were performed at the specific time
points indicated using a Bayer Contour blood glucose meter and
test strips. For glucose-stimulated insulin secretion assays, mice
were fasted overnight and injected with 1 g kg1 glucose;
15 min after injection, 50 lL of blood was collected in a
heparinized tube. For fasting and refed blood glucose levels,
mice were fasted overnight, and blood glucose was determined
as above. 50 lL of blood was collected in heparinized tubes, and
mice were refed for 4 h. Blood glucose levels were again
determined, and another 50 lL of blood was collected in
heparinized tubes. Blood samples were spun at 5400 g for
10 min in a refrigerated centrifuge, and plasma was collected and
kept at 80 °C until analysis. Plasma insulin levels were deter-
mined by ELISA, performed by the U. Penn Diabetes Research
Center core facility.
Glycated hemoglobin (HbA1c)
Hemoglobin A1c was measured as detailed in the Beckman Coulter
SYNCHRON Systems Chemistry information sheet A18497 (https://
www.beckmancoulter.com/wsrportal/techdocs?docname=/cis/A18
497/AG/EN_HbA1c.pdf). Total hemoglobin concentration was mea-
sured by a standard colorimetric method, while hemoglobin A1c
antibodies combine with hemoglobin A1c from the sample to form
soluble antigen–antibody complexes. Polyhaptens from the reagent
then bind with the excess antibodies, and the resulting agglutinated
complex is measured turbidimetrically by absorbance at 340 nanom-
eters. These are used to express hemoglobin A1c concentration as a
percentage of total hemoglobin.
Fructosamine
Fructosaminewasmeasured as detailed in the Polymedco information
sheet, using the enzymatic assay of the Poly-Chem System (http://
www.polymedco.com/chemistries—special-chemistries-pages-111.
php). To measure fructosamine, a proteinase digests the glycated
protein to yield glycated protein fragments. Ketamine oxidase
oxidizes the ketamine bond of the glycated protein fragments. As a
result, hydrogen peroxide is released and measured in a colorimetric
Trinder end-point reaction.
Statistical analysis and HOMA2-IR
All comparisons were performed using two-tailed t-tests. Area
under the curve was calculated using Prism (GraphPad Software).
HOMA2-IR was calculated using the fasted blood glucose levels and
fasting insulin levels of mice fasted overnight for 16 h, using the
HOMA2-IR calculator (http://www.dtu.ox.ac.uk/homacalculator/
index.php) (Wallace et al., 2004).
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